|Bid||1.0600 x 3000|
|Ask||1.1200 x 3000|
|Day's range||1.0411 - 1.1450|
|52-week range||0.9100 - 6.8700|
|Beta (5Y monthly)||2.49|
|PE ratio (TTM)||N/A|
|Earnings date||05 Mar 2024 - 11 Mar 2024|
|Forward dividend & yield||N/A (N/A)|
|1y target est||9.25|
Key Insights Given the large stake in the stock by institutions, Seres Therapeutics' stock price might be vulnerable to...
CAMBRIDGE, Mass., November 28, 2023--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Seres management will participate at the Piper Sandler 35th Annual Healthcare Conference on Wednesday, November 29, 2023, at 3:30 p.m. ET.
Flagship Pioneering, the bioplatform innovation company, today unveiled Quotient Therapeutics, a company pioneering somatic genomics, the study of genetic variation at the cellular level, to discover therapeutics informed by new links between genes and disease. Flagship has made an initial commitment of $50 million to advance development of the company's platform following two years of development at Flagship Labs and pursue a pipeline of medicines across a wide range of therapeutic areas and mo